Search
On this page:
Support faster stable cell line development
Stable cell line development programs for monoclonal antibodies (mAbs), mAb variants, and Fc-fusion proteins often face extended selection timelines, suboptimal titers from legacy expression systems, complex licensing terms, and the burden of sourcing cells, vectors, and media from multiple suppliers.
The Gibco CHOvantage GS Cell Line Development Kit helps enable rapid development of high-performing cell lines, enabling the delivery of highly productive pools in as little as 4 weeks and stable clones in just 14 weeks. Built on a CHO-K1 platform capable of achieving mAb titers ≥7 g/L, it combines a transposon-based vector system for consistent protein quality with royalty-free commercial licensing to help reduce overall development costs.
See the CHOvantage GS Cell Line Development Kit in action
Learn how the platform combines a transposon vector system, optimized media and feeds, and simplified licensing to support efficient development of high-producing clones.
What the Gibco CHOvantage GS Kit includes
The CHOvantage GS Cell Line Development Kit is designed to enhance the complete workflow from gene of interest through stable clone selection, with the primary components included in a single kit.
Kit contents include:
- cGMP-banked CHO-K1 GS cells
- Gibco pCHOvantage DNA vector
- Gibco CHOvantage mRNA
- Gibco Efficient-Pro Medium (+) Insulin
- Gibco Efficient-Pro Feed 3
- Gibco Efficient-Pro Feed Enhancer
- Full protocol and workflow documentation
The Gibco CHOvantage mRNA is also available as a standalone item. It is available exclusively to customers who purchased the CHOvantage GS Cell Line Development Kit.
Transposon vector system for semi-targeted gene integration
The CHOvantage DNA vector contains the genetic elements driving gene expression, while CHOvantage mRNA encodes the transposase that facilitates semi-targeted integration into the CHO-K1 genome.
Benefits include:
- High transfection efficiency
- Reduced positional effects compared with random integration
- More uniform expression across stable pools
- Clonal stability up to 100 generations tested in fed-batch culture
- Shorter development timelines
Accelerated workflow from transfection to stable clone
The Gibco CHOvantage GS Cell Line Development Kit supports the generation of stable pools in approximately 4 weeks from transfection and an additional 10 weeks to stable clones.
The workflow progresses through six stages:
- Transfection
- Application of selective pressure
- Pool assessment
- Single-cell sorting (FACS)
- Lead clone screening
- Stable lead clone RCB creation
The Gibco Efficient-Pro Media and Feeds System is integrated throughout this workflow to enhance CHO-K1 fed-batch productivity from early culture through stable clone expansion.
Performance and productivity in CHO-K1 cell line development
Enable high productivity and performance during CHO-K1 cell line development with the kit. Across multiple culture scales, lead clones demonstrate robust antibody expression and reproducible titers under recommended fed-batch conditions.
Figure 1. mAb productivity across culture scales. Consistent productivity was observed for a lead monoclonal antibody clone, with average titers ranging from approximately 6.8–7.7 g/L across scales.
Figure 2. bsAb productivity across culture scales. Consistent titers were also observed for a lead bispecific antibody clone, with productivity ranging from approximately 5.8–6.3 g/L across microbioreactor runs and 5 L bioreactor cultures.
Choose the right cell line development kit
The Gibco portfolio of cell line development kits spans multiple Chinese hamster ovary (CHO) host cell lines and applications, allowing scientists to select a kit aligned with their CHO host cell line preference, target molecule, and development timeline.
Host cell line |
Selection system |
Primary application |
|
CHO-K1 |
Glutamine synthetase |
mAb production and mAb variants |
|
ExpiCHO-S |
Puromycin |
mAb and recombinant protein |
|
CHO-S |
Puromycin |
mAb production |
|
DG44 |
Methotrexate/DHFR |
mAb and recombinant protein |
Ordering information
Related resources
Frequently asked questions
The CHOvantage transposon vector system uses a two-part design, a pCHOvantage DNA vector encoding the gene of interest paired with CHOvantage RNA, which creates the transposase, to achieve semi-targeted integration into the CHO-K1 genome. Compared to random integration methods, semi-targeted integration can produce more uniform expression across clones and reduce the number of clones that must be screened to identify high producers. This can shorten clone selection timelines and reduce associated screening costs.
The CHOvantage GS kit routinely generates mAb titers of greater than 7 g/L and bispecific antibody and fusion protein titers of greater than 6 g/L in fed-batch cultures under recommended protocol conditions. Actual titers will vary depending on the specific molecule, cell culture conditions, and process parameters. Titer data should be evaluated in the context of the individual development program and molecule characteristics rather than as absolute minimums.
Purchase of the kit includes research-use rights for the purchaser and their designated CRO to develop a stable cell line. No annual maintenance fees or added costs are required to maintain research rights. When transitioning to clinical or commercial manufacturing, a simplified commercial licensing structure is available that excludes royalties and multiple milestone payments. For details on commercial licensing terms, contact outlicensing@thermofisher.com.
The CHOvantage workflow is designed to enable faster progression to stable pools and clones compared to traditional approaches. Stable pools can be generated in 4 weeks from transfection to stable pool, and then an additional 10 weeks from stable pools to the selection of lead stable clones. The integration of the Efficient-Pro Media and Feeds System and the transposon vector design enables this advanced timeline.
Additional bioprocessing resources
Bioprocessing resources
For Research Use Only. Not for use in diagnostic procedures.